Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDA001 in Moderate-to-Severe Crohn's Disease
NCT01155362Phase 2Completed
- Sponsor
- Celularity Inc.
- Start
- Aug 2010
- Primary completion
- Feb 2012
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PDA001 in Crohn's disease (4 arms), sponsored by Celularity Inc. Primary endpoint: Induction of Clinical Response at 6 weeks. Started Aug 2010; status: completed.
02
Drugs
PDA001
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01155362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01155362.